Want to see DE:AJ91 full AI Analyst Report?
DocCheck AG (AJ91) AI Stock Analysis
DocCheck AG
(XETRA:AJ91)
The overall score is weighed down by extremely poor technical momentum, with the stock in a clear downtrend. This is partially offset by a very attractive valuation, featuring a low P/E and a high dividend yield, and a stable, low-debt balance sheet. The primary risk is the weak price trend and declining cash flow generation, while the main support comes from the company's solid financial foundation and compelling income return.
DocCheck AG (AJ91) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 53.28M
- Dividend Yield
- 9.52%
- Average Volume (3M)
- 500
- Price to Earnings (P/E)
- 11.4
- Beta (1Y)
- 0.43
- Revenue Growth
- 1.35%
- EPS Growth
- -20.52%
- Country
- Germany
- Employees
- 414
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
DocCheck AG Business Overview & Revenue Model
Company Description
DocCheck AG offers community, agency, and e-commerce services for the healthcare sector in Europe. The company develops and implements communication strategies for media on healthcare and business-to-business sectors; sells medical supplies and medic...
How the Company Makes Money
DocCheck AG primarily generates revenue by selling digital marketing, communication, and related online services to customers in the healthcare and life-sciences industry, using its healthcare-professional-focused online environment and audience acce...
DocCheck AG Financial Statement Overview
Summary
The balance sheet is strong with low debt and healthy ROE, but income and cash flow scores are weaker due to subdued revenue growth, margin pressure, and declining free cash flow. The overall financial picture is mixed, leaning slightly positive due to financial stability.
Income Statement
52NeutralBalance Sheet
78PositiveCash Flow
48Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.65M | 55.32M | 53.79M | 53.41M | 60.90M | 85.92M |
| Gross Profit | 10.57M | 12.28M | 10.53M | 12.97M | 14.08M | 21.54M |
| EBITDA | 10.02M | 10.39M | 10.18M | 9.38M | 13.38M | 20.09M |
| Net Income | 4.66M | 5.33M | 5.28M | 2.27M | 6.29M | 11.40M |
Balance Sheet | ||||||
| Total Assets | 53.40M | 55.68M | 60.86M | 56.14M | 63.28M | 60.25M |
| Cash, Cash Equivalents and Short-Term Investments | 15.98M | 18.54M | 21.02M | 17.52M | 15.66M | 21.52M |
| Total Debt | 2.76M | 4.16M | 5.01M | 5.85M | 7.07M | 7.03M |
| Total Liabilities | 15.08M | 14.07M | 20.78M | 18.11M | 23.86M | 22.08M |
| Stockholders Equity | 38.32M | 41.61M | 40.08M | 37.33M | 38.57M | 37.31M |
Cash Flow | ||||||
| Free Cash Flow | 1.52M | 2.61M | 6.82M | 5.62M | -557.91K | 6.90M |
| Operating Cash Flow | 5.26M | 6.14M | 7.82M | 7.51M | 5.89M | 10.92M |
| Investing Cash Flow | -2.65M | -3.81M | -1.48M | -1.93M | -4.92M | -4.39M |
| Financing Cash Flow | -6.07M | -4.88M | -3.50M | -4.60M | -5.81M | -5.86M |
DocCheck AG Peers Comparison
Overall Rating
DE:M3V68Neutral- DE:AJ9158Neutral
DE:ILM155Neutral
DE:COP53Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| DE:M3V | 68Neutral | EUR 37.13M | 26.84 | 7.77% | 4.66% | -6.92% | -67.82% |
| DE:AJ91 | 58Neutral | EUR 53.28M | 11.41 | 11.67% | 9.52% | 1.35% | -20.52% |
| DE:ILM1 | 55Neutral | EUR 269.85M | 24.05 | 2.16% | ― | 9.88% | -38.44% |
| DE:COP | 53Neutral | EUR 1.50B | 43.42 | 4.19% | 1.74% | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:AJ91 | DocCheck AG | 10.50 | -0.80 | -7.10% | |
| DE:COP | CompuGroup Medical | 28.45 | 4.29 | 17.74% | |
| DE:M3V | MeVis Medical Solutions | 20.40 | -3.89 | -16.00% | |
| DE:ILM1 | Medios AG | 10.58 | -1.68 | -13.70% | |
| DE:MDQ | MediNavi AG | 3.80 | -0.20 | -5.00% | |
| DE:5NB | Novetum AG | 41.00 | 12.40 | 43.36% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 22, 2026